We used different AD sources to investigate the biomarker potential of miR‐501‐3p and miR‐502‐3p in relation to Aβ and Tau pathology: (1) CSF, (2) serum, (3) fibroblasts, (4) B‐lymphocytes, (5) APP and Tau plasmid transfected cells and (6) brain cells. This evidence concerns the gene MAPT and Alzheimer disease.